Investor Presentaiton
Our clinical mission: support the patient every step of the way
PSA
Localised disease
Radiation therapy +/- ADT
Radical prostatectomy
Active surveillance
68Ga/ 99mTc
imaging
Advancing clinical stages
Docetaxel, abiraterone (metastatic,
non-castrate), apalutamide,
enzalutamide, darolutamide
(non-metastatic, castrate resistant)
Metastatic castrate resistant
First line:
Docetaxel; Sipuleucel-T; Abiraterone
Enzalutamide
For personal use only
PROSTACT
TARGET
Asymptomatic
Non-metastatic
Castration-sensitive
Rising PSA
ADT (non-castrate)
Combination of EBRT
and TLX591 in early
PROSTACT
SELECT
Radiogenomics and
tumour targeting of
TLX591
biochemical recurrence
CUPID
TLX592 (225Ac)
Second line:
Cabazitaxel; Abiraterone
Enzalutamide; Radium 223
Olaparib; Rucaparib
Telix Pharmaceuticals Limited (ASX: TLX)
Time / disease progression
PROSTACT
GLOBAL
Second line +
Clinical trial
TELIX
PHARMACEUTICALS
PROSTACT ?
PSMA-617 failures
CUPID
Pivotal Phase III study in patients with
mCRPC progressing on 1st line novel
androgen agents
Symptomatic
Metastatic
Castration-resistant
36View entire presentation